Gene interactions and pathways from curated databases and text-mining

◀ Back to JAK2

JAK2 — STAT6

Pathways - manually collected, often from reviews:

Text-mined interactions from Literome

Deng et al., Biochem Biophys Res Commun 2000 : In this report, we provide evidence that interleukin 4 (IL-4) induced JAK2 mediated STAT6 tyrosine phosphorylation and DNA binding in 3T3-L1 preadipocytes but not in 3T3-L1 adipocytes
Murata et al., Int J Hematol 1999 : While JAK3 is required for signal transducer and activator of transcription-6 ( STAT6 ) activation in hematopoietic cells, we recently demonstrated that in nonhematopoietic cells JAK2 is required for STAT6 activation for the alternative form of IL-4R
Yamaura et al., Am J Physiol Heart Circ Physiol 2003 (Myocardial Infarction...) : Tyrphostin AG490, a JAK2 inhibitor, or 4-amino-5- ( 4-methylphenyl ) -7- ( t-butyl ) -pyrazolo-3,4-d-pyrimidine ( PPI ), a Src kinase blocker, blocked STAT5A phosphorylation, whereas STAT6 phosphorylation was blocked only with tyrphostin
Deszo et al., Cell Signal 2004 : JAK inhibition with WHI-P154 abrogated IL-4 dependent CD11b and CD86 up-regulation and inhibited STAT6 tyrosine phosphorylation
Nath et al., J Immunol 2004 (Encephalomyelitis, Autoimmune, Experimental...) : Lovastatin induced the expression of GATA3 and the phosphorylation of STAT6 , whereas it inhibited tyrosine phosphorylation of Janus kinase 2 , tyrosine kinase 2, and STAT4
Guiter et al., Blood 2004 (Lymphoma, B-Cell...) : MedB1 treatment with JAK2 inhibitor AG490 partially decreased STAT6 phosphorylation, suggesting that JAK2 is partially involved in STAT6 activation in these cells
Mottok et al., Blood 2007 (Hodgkin Disease) : Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6
Nishimura et al., Circ J 2008 : IL-13 has anti-angiogenic activity as a result of activation of JAK2 and subsequent activation of STAT6
Chi et al., Exp Cell Res 2010 (Lung Neoplasms) : Inhibitors of JAKs, kaempferol and JAK inhibitor I, attenuated IL-4 stimulated STAT6 phosphorylation and 15-PGDH activity in a comparable concentration dependent manner
Bhattacharjee et al., Free Radic Biol Med 2013 : We further show that Jak2 is upstream of Stat3 activation and Tyk2 controls Stat1 and Stat6 activation in response to IL-13 stimulation
Murata et al., Blood 1998 : Because IL-4 phosphorylates JAK1 and JAK2 tyrosine kinases in nonhematopoietic cells, we investigated whether JAK1 and JAK2 are required for IL-4 induced STAT6 activation in various transfectants ... Cotransfection experiments with different chains of IL-4R and kinase-deficient JAK1 and JAK2 mutants in CHO cells showed that JAK1 and JAK2 are required for optimal activation of STAT6 in the alpha ' beta transfectant but only partially in the beta gammac transfectant ... Taken together, our results show that IL-13Ralpha ' is a novel functional component of the IL-4R system and that JAK1 and JAK2 mediate IL-4 induced optimal activation of STAT6 in nonhematopoietic cells